Work

Reduced Risk of Progressive Multifocal Leukoencephalopathy (PML) with Natalizumab Extended Interval Dosing (EID) Compared with Every-4-week (Q4W) Dosing: Updated Analysis of the TOUCH® Prescribing Program Database (P10-6.005)

Year: 2024

Type: article

Source: Neurology

DOI: 10.1212/wnl.0000000000204375

Authors: Lana Zhovtis Ryerson, John Foley, Ilya Kister, Gary Cutter, Ryan Metzger, Judith Goldberg, Xiaochun Li, Evan Riddle, Karen Smirnakis, Rose Domingo-Horne, Tyler Lasky

Institutions: Jersey Shore University Medical Center, Rocky Mountain Multiple Sclerosis Clinic, NYU Langone Health, New York University, University of Alabama at Birmingham, Biogen (United States)

Language: English

Topic: Polyomavirus and related diseases

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4394599236

FWCI: 0.532

Cites:

Cited by: 3

Related to: 10